|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US7935675B1
(en)
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
|
EP0909323B1
(en)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Helicobacter pylori bacterioferritin
|
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
|
ES2195317T3
(es)
|
1997-01-30 |
2003-12-01 |
Chiron Corp |
Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
|
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
EP1003531B1
(en)
|
1997-05-20 |
2007-08-22 |
Ottawa Health Research Institute |
Processes for preparing nucleic acid constructs
|
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
|
WO1998055609A1
(en)
|
1997-06-06 |
1998-12-10 |
The Regents Of The University Of California |
Inhibitors of dna immunostimulatory sequence activity
|
|
US7138384B1
(en)
|
1997-08-29 |
2006-11-21 |
The Regents Of The University Of California |
Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6218371B1
(en)
|
1998-04-03 |
2001-04-17 |
University Of Iowa Research Foundation |
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
|
|
DK1079824T3
(da)
|
1998-05-19 |
2011-11-21 |
Res Dev Foundation |
Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf
|
|
DK1077722T3
(da)
|
1998-05-22 |
2006-11-27 |
Ottawa Health Research Inst |
Fremgangsmåder og produkter til induktion af mukosaimmunitet
|
|
ATE315405T1
(de)
|
1998-08-10 |
2006-02-15 |
Antigenics Inc |
Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
|
|
FR2783170B1
(fr)
*
|
1998-09-11 |
2004-07-16 |
Pasteur Merieux Serums Vacc |
Emulsion immunostimulante
|
|
US6887464B1
(en)
|
1999-02-02 |
2005-05-03 |
Biocache Pharmaceuticals, Inc. |
Advanced antigen presentation platform
|
|
CA2361377C
(en)
*
|
1999-02-05 |
2009-02-03 |
Alk-Abello A/S |
Novel mucosal delivery system
|
|
AU2457100A
(en)
*
|
1999-02-26 |
2000-09-14 |
Chiron S.P.A. |
Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
|
|
WO2000050006A2
(en)
|
1999-02-26 |
2000-08-31 |
Chiron Corporation |
Microemulsions with adsorbed macromoelecules and microparticles
|
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
|
DK1187629T3
(da)
|
1999-04-19 |
2005-01-17 |
Glaxosmithkline Biolog Sa |
Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
|
|
EP1177439B1
(en)
*
|
1999-04-29 |
2004-09-08 |
Coley Pharmaceutical GmbH |
Screening for immunostimulatory dna functional modifiers
|
|
AP1891A
(en)
*
|
1999-05-06 |
2008-09-23 |
The Immune Response Corp |
HIV immunogenic compositions and methods.
|
|
US6737066B1
(en)
|
1999-05-06 |
2004-05-18 |
The Immune Response Corporation |
HIV immunogenic compositions and methods
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
|
US7479285B1
(en)
|
1999-08-19 |
2009-01-20 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
|
AU780535B2
(en)
*
|
1999-08-27 |
2005-03-24 |
Inex Pharmaceuticals Corp. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
|
GB9921147D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
|
WO2001022972A2
(en)
|
1999-09-25 |
2001-04-05 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acids
|
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
|
EP1950296B1
(en)
*
|
2000-01-14 |
2014-05-07 |
The Government of the United States of America, as represented by the Secretary of Health and Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
WO2001051500A1
(en)
*
|
2000-01-14 |
2001-07-19 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
US20010044416A1
(en)
*
|
2000-01-20 |
2001-11-22 |
Mccluskie Michael J. |
Immunostimulatory nucleic acids for inducing a Th2 immune response
|
|
US7585847B2
(en)
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
|
US7157437B2
(en)
*
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
|
US20020107212A1
(en)
*
|
2000-03-10 |
2002-08-08 |
Nest Gary Van |
Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
|
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
|
US20020028784A1
(en)
*
|
2000-03-10 |
2002-03-07 |
Nest Gary Van |
Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
|
|
US20010046967A1
(en)
*
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
|
EP1278542A2
(en)
*
|
2000-05-05 |
2003-01-29 |
Cytos Biotechnology AG |
Molecular antigen arrays and vaccines
|
|
EP1296714B1
(en)
*
|
2000-06-22 |
2009-08-26 |
University Of Iowa Research Foundation |
Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
|
|
EP1366077B1
(en)
|
2000-09-15 |
2011-05-25 |
Coley Pharmaceutical GmbH |
PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
|
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
|
WO2002069369A2
(en)
|
2000-12-08 |
2002-09-06 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
|
EP1364010B1
(en)
|
2000-12-27 |
2010-06-16 |
Dynavax Technologies Corporation |
Immunomodulatory polynucleotides and methods of using the same
|
|
US7094409B2
(en)
|
2001-01-19 |
2006-08-22 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of allergic eosinophilic diseases
|
|
EP1390494A2
(en)
|
2001-05-21 |
2004-02-25 |
Intercell AG |
Method for stabilising of nucleic acids
|
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
|
KR100985457B1
(ko)
|
2001-06-21 |
2010-10-06 |
다이나박스 테크놀로지 코퍼레이션 |
키메라 면역조절 화합물 및 그것들의 사용 방법
|
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
|
AU2002326561B2
(en)
|
2001-08-07 |
2008-04-03 |
Dynavax Technologies Corporation |
Immunomodulatory compositions, formulations, and methods for use thereof
|
|
US7354909B2
(en)
|
2001-08-14 |
2008-04-08 |
The United States Of America As Represented By Secretary Of The Department Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
|
EA007232B1
(ru)
|
2001-08-17 |
2006-08-25 |
Коли Фармасьютикал Гмбх |
Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
|
|
EP2518142B1
(en)
|
2001-08-24 |
2015-07-15 |
UVic Industry Partnerships Inc. |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
|
EP1450856B1
(en)
|
2001-09-14 |
2009-11-11 |
Cytos Biotechnology AG |
Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
|
|
AU2002353783A1
(en)
|
2001-09-24 |
2003-04-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
|
WO2004012669A2
(en)
|
2002-08-01 |
2004-02-12 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
|
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
|
KR20050048539A
(ko)
*
|
2001-10-06 |
2005-05-24 |
메리얼엘엘씨 |
CpG 제제 및 관련된 방법
|
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
US20060210555A1
(en)
|
2001-12-21 |
2006-09-21 |
Antigenics, Inc. |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
|
AU2003203079B9
(en)
|
2002-02-04 |
2009-01-15 |
Oncothyreon Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
|
JP4646516B2
(ja)
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
|
KR20040105740A
(ko)
|
2002-02-25 |
2004-12-16 |
엘란 파마슈티칼스, 인크. |
염증 치료제의 투여 방법
|
|
IL163812A0
(en)
|
2002-03-05 |
2005-12-18 |
Univ Ramot |
Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
|
|
NZ535952A
(en)
|
2002-04-04 |
2009-01-31 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
|
BR0312792A
(pt)
|
2002-07-19 |
2005-05-03 |
Cytos Biotechnology Ag |
Composições de vacinas contendo séries antigênicas de amilóide beta1-6
|
|
JP2005533855A
(ja)
|
2002-07-24 |
2005-11-10 |
インターツェル・アクチェンゲゼルシャフト |
病原性ウイルスからの別のリーディングフレームによりコードされる抗原
|
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
|
EP1537418A2
(en)
|
2002-09-13 |
2005-06-08 |
Intercell AG |
Method for isolating hepatitis c virus peptides
|
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
EP2351579B1
(en)
|
2002-10-11 |
2016-09-21 |
Novartis Vaccines and Diagnostics S.r.l. |
Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
|
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
CA2506318C
(en)
|
2002-11-15 |
2011-07-12 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
|
US7956043B2
(en)
|
2002-12-11 |
2011-06-07 |
Coley Pharmaceutical Group, Inc. |
5′ CpG nucleic acids and methods of use
|
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
|
DK1992635T3
(da)
|
2002-12-23 |
2012-03-05 |
Dynavax Tech Corp |
Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
|
|
EP2263687B1
(en)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions containing phospholipid
|
|
DK1587537T3
(da)
|
2003-01-30 |
2012-07-16 |
Novartis Ag |
Injicerbare vacciner mod multiple meningococ-serogrupper
|
|
WO2004074454A2
(en)
|
2003-02-20 |
2004-09-02 |
University Of Connecticut Health Center |
Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
|
|
AU2004224746B2
(en)
|
2003-03-24 |
2009-04-23 |
Valneva Austria Gmbh |
Improved vaccines
|
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
|
CN101675993A
(zh)
|
2003-03-26 |
2010-03-24 |
赛托斯生物技术公司 |
Melan-a肽类似物-病毒样颗粒偶联物
|
|
US20060257852A1
(en)
|
2003-04-10 |
2006-11-16 |
Chiron Corporation |
Severe acute respiratory syndrome coronavirus
|
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
|
DK2361928T3
(en)
|
2003-05-19 |
2017-07-03 |
Prothena Biosciences Ltd |
Truncated fragments of alpha synuclein in Lewy body disease
|
|
ES2596553T3
(es)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
|
US8541002B2
(en)
|
2003-09-12 |
2013-09-24 |
Agenus Inc. |
Vaccine for treatment and prevention of herpes simplex virus infection
|
|
ES2397923T3
(es)
|
2003-10-02 |
2013-03-12 |
Novartis Ag |
Vacunas líquidas para múltiples serogrupos meningocócicos
|
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
|
US20080254065A1
(en)
|
2004-03-09 |
2008-10-16 |
Chiron Corporation |
Influenza Virus Vaccines
|
|
EP2545931A1
(en)
|
2004-03-19 |
2013-01-16 |
Herbs Spring, LLC |
Herbal therapy for the treatment of food allergy
|
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
|
RU2379052C2
(ru)
|
2004-04-30 |
2010-01-20 |
Чирон С.Р.Л. |
Вакцинация менингококковыми конъюгатами
|
|
AU2005247341B2
(en)
|
2004-05-06 |
2008-05-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
|
US20090104226A1
(en)
|
2004-05-21 |
2009-04-23 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus Vectors for Respiratory Pathogen Vaccines
|
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
|
MX2007001679A
(es)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
|
|
EP2149583B1
(en)
|
2004-09-24 |
2015-10-28 |
Novartis AG |
Modified VP1-capsid protein of parvovirus B19
|
|
KR20070094890A
(ko)
|
2004-10-25 |
2007-09-27 |
머크 앤드 캄파니 인코포레이티드 |
안티 addl 항체 및 그 용도
|
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
|
GB0424563D0
(en)
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
CN101107007B
(zh)
|
2005-01-27 |
2011-08-17 |
奥克兰儿童医院及研究中心 |
对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
|
|
JP4836145B2
(ja)
*
|
2005-01-28 |
2011-12-14 |
クウォン,ヒュン−ジョ |
マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および/または正常免疫細胞保護用オリゴヌクレオチド
|
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
尿路病原性菌株由来の抗原
|
|
WO2006110655A2
(en)
|
2005-04-08 |
2006-10-19 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
|
EP1871411A4
(en)
|
2005-04-18 |
2010-07-21 |
Novartis Vaccines & Diagnostic |
EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
|
|
CN101238145B
(zh)
|
2005-06-14 |
2013-04-24 |
普罗陶克斯有限公司 |
修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用
|
|
SI2380584T1
(sl)
|
2005-07-01 |
2014-04-30 |
Index Pharmaceuticals Ab |
Imunostimulatorni postopek
|
|
PT2179737E
(pt)
|
2005-07-01 |
2013-12-05 |
Index Pharmaceuticals Ab |
Método para modular a capacidade de resposta aos esteróides
|
|
EP2614709A1
(en)
|
2005-07-18 |
2013-07-17 |
Novartis AG |
Small animal model for HCV replication
|
|
EP1945247A1
(en)
|
2005-10-18 |
2008-07-23 |
Novartis Vaccines and Diagnostics, Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
|
AU2006306805A1
(en)
|
2005-10-28 |
2007-05-03 |
Index Pharmaceuticals Ab |
Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
|
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
WO2007052055A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
ES2377884T3
(es)
|
2005-11-04 |
2012-04-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
|
|
NZ594482A
(en)
|
2005-11-04 |
2012-11-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
|
|
CA2628424A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
|
PL2478916T3
(pl)
|
2006-01-27 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
|
|
ES2555544T3
(es)
|
2006-03-07 |
2016-01-04 |
Vaxinnate Corporation |
Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
|
|
ATE539079T1
(de)
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
|
WO2007110776A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
|
EP2017281A4
(en)
|
2006-04-14 |
2012-03-14 |
Kyowa Hakko Kirin Co Ltd |
AGONISTS AT TOLL-LIKE RECEPTOR 9
|
|
US8357781B2
(en)
|
2006-06-01 |
2013-01-22 |
Janssen Alzheimer Immunotherapy |
Neuroactive fragments of APP
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
NZ575271A
(en)
|
2006-09-11 |
2011-09-30 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
|
JP2011506264A
(ja)
|
2006-12-06 |
2011-03-03 |
ノバルティス アーゲー |
インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
PL2583978T3
(pl)
|
2007-02-23 |
2016-07-29 |
Prothena Biosciences Ltd Co |
Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
|
|
LT3067066T
(lt)
|
2007-02-23 |
2019-06-25 |
Prothena Biosciences Limited |
Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
|
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
US8287885B2
(en)
|
2007-09-12 |
2012-10-16 |
Novartis Ag |
GAS57 mutant antigens and GAS57 antibodies
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
AU2008335457B2
(en)
|
2007-12-07 |
2015-04-16 |
Glaxosmithkline Biologicals S.A. |
Compositions for inducing immune responses
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
NZ586430A
(en)
|
2007-12-21 |
2012-09-28 |
Novartis Ag |
Mutant forms of streptolysin o (slo)
|
|
WO2009086539A2
(en)
|
2007-12-28 |
2009-07-09 |
Elan Pharmaceuticals, Inc. |
Treatment and prophylaxis of amyloidosis
|
|
AU2009215364B2
(en)
|
2008-02-21 |
2014-09-18 |
Glaxosmithkline Biologicals S.A. |
Meningococcal fHBP polypeptides
|
|
AU2009223613B2
(en)
|
2008-03-10 |
2014-09-25 |
Children's Hospital & Research Center At Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
|
JP5518041B2
(ja)
|
2008-03-18 |
2014-06-11 |
ノバルティス アーゲー |
インフルエンザウイルスワクチン抗原の調製における改良
|
|
SG190562A1
(en)
|
2008-04-18 |
2013-06-28 |
Vaxinnate Corp |
Deletion mutants of flagellin and methods of use
|
|
EP2278979A4
(en)
|
2008-05-21 |
2012-09-26 |
Us Gov Health & Human Serv |
PROCESS FOR TREATING PNEUMOCONIOSIS WITH OLIGODESOXYNUCLEOTIDES
|
|
ES2569907T3
(es)
|
2008-06-27 |
2016-05-13 |
Zoetis Services Llc |
Composiciones adyuvantes novedosas
|
|
NZ591768A
(en)
|
2008-09-18 |
2012-11-30 |
Novartis Ag |
Vaccine adjuvant combinations
|
|
BRPI0922561A2
(pt)
|
2008-12-09 |
2020-08-11 |
Pfizer Vaccines Llc |
vacina de peptídeo de ch3 da ige.
|
|
WO2010079464A1
(en)
|
2009-01-12 |
2010-07-15 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
|
EA023662B1
(ru)
|
2009-02-10 |
2016-06-30 |
Новартис Аг |
Вакцины против гриппа со сниженным количеством сквалена
|
|
WO2010100632A2
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
|
CN104548082A
(zh)
|
2009-03-24 |
2015-04-29 |
诺华股份有限公司 |
为脑膜炎球菌因子h结合蛋白添加佐剂
|
|
AU2010232490B2
(en)
|
2009-04-03 |
2016-08-11 |
Agenus Inc. |
Methods for preparing and using multichaperone-antigen complexes
|
|
EP2419129A2
(en)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Compositions for immunising against staphylococcus aerus
|
|
WO2010138193A2
(en)
|
2009-05-27 |
2010-12-02 |
Selecta Biosciences, Inc. |
Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
|
|
CA2765364C
(en)
|
2009-06-15 |
2015-05-26 |
National University Of Singapore |
Influenza vaccine, composition, and methods of use
|
|
EP4183412B1
(en)
|
2009-07-15 |
2024-08-14 |
GlaxoSmithKline Biologicals SA |
Rsv f protein compositions and methods for making same
|
|
CA2768343A1
(en)
|
2009-07-16 |
2011-01-20 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
|
CN102596236B
(zh)
|
2009-07-30 |
2015-06-24 |
辉瑞疫苗有限责任公司 |
抗原性Tau肽及其用途
|
|
AU2010288239B2
(en)
|
2009-08-27 |
2014-01-16 |
Novartis Ag |
Adjuvant comprising aluminium, oligonucleotide and polycation
|
|
WO2011024072A2
(en)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
|
KR101660578B1
(ko)
|
2009-09-03 |
2016-09-27 |
화이자 백신스 엘엘씨 |
Pcsk9 백신
|
|
CN102695523A
(zh)
|
2009-09-10 |
2012-09-26 |
诺华有限公司 |
针对呼吸道疾病的组合疫苗
|
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
|
US8974799B2
(en)
|
2009-09-30 |
2015-03-10 |
Novartis Ag |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
SG181628A1
(en)
|
2009-12-22 |
2012-07-30 |
Celldex Therapeutics Inc |
Vaccine compositions
|
|
CA2789443C
(en)
|
2010-02-12 |
2016-09-13 |
Chimerix, Inc. |
Nucleoside phosphonate salts
|
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
WO2012020326A1
(en)
|
2010-03-18 |
2012-02-16 |
Novartis Ag |
Adjuvanted vaccines for serogroup b meningococcus
|
|
TR201802933T4
(tr)
|
2010-03-30 |
2018-03-21 |
Childrens Hospital & Res Center At Oakland |
Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
|
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
US9744228B2
(en)
|
2010-04-07 |
2017-08-29 |
Norvartis Ag |
Method for generating a parvovirus B19 virus-like particle
|
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
|
CN107029223A
(zh)
|
2010-05-26 |
2017-08-11 |
西莱克塔生物科技公司 |
合成纳米载体联合疫苗
|
|
CN102933267B
(zh)
|
2010-05-28 |
2015-05-27 |
泰特里斯在线公司 |
交互式混合异步计算机游戏基础结构
|
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
|
EP2575868A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
WO2011161653A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
|
CA2804501C
(en)
|
2010-07-06 |
2021-01-26 |
Novartis Ag |
Noro virus derived immunogenic compositions and methods
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
US20130115227A1
(en)
|
2010-07-14 |
2013-05-09 |
Renee C. Gaspar |
Anti-addl monoclonal antibody and uses thereof
|
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
|
EP2640190A4
(en)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
|
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
|
ES3018416T3
(es)
|
2011-01-26 |
2025-05-16 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
|
AR086199A1
(es)
|
2011-04-22 |
2013-11-27 |
Wyeth Llc |
Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
|
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
|
AU2012262021B2
(en)
|
2011-06-01 |
2016-07-28 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
|
BR112013030894A2
(pt)
|
2011-06-01 |
2016-08-16 |
Janus Biotherapeutics Inc |
moduladores do sistema imune
|
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
诺华股份有限公司 |
酪氨酸连接方法
|
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
|
JP2014521687A
(ja)
|
2011-07-29 |
2014-08-28 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
体液性および細胞傷害性tリンパ球(ctl)免疫応答を生成する合成ナノキャリア
|
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
|
US9511130B2
(en)
|
2011-09-14 |
2016-12-06 |
Glaxosmithkline Biologicals Sa |
Escherichia coli vaccine combination
|
|
EP2755683B1
(en)
|
2011-09-14 |
2019-04-03 |
GlaxoSmithKline Biologicals SA |
Methods for making saccharide-protein glycoconjugates
|
|
CA2850932A1
(en)
|
2011-10-04 |
2013-04-11 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
|
RU2636350C2
(ru)
|
2011-11-07 |
2017-11-22 |
Новартис Аг |
МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
|
|
AU2012349753A1
(en)
|
2011-12-08 |
2014-06-19 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
|
US12268718B2
(en)
|
2012-01-16 |
2025-04-08 |
Labyrinth Holdings Llc |
Control of cellular redox levels
|
|
SG10202013014RA
(en)
|
2012-01-16 |
2021-02-25 |
Mckenna Elizabeth |
Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
|
|
US20140086849A1
(en)
*
|
2012-09-21 |
2014-03-27 |
Elizabeth McKenna |
Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof
|
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
|
CN104321335A
(zh)
|
2012-02-24 |
2015-01-28 |
诺华股份有限公司 |
菌毛蛋白质和组合物
|
|
WO2013163176A1
(en)
|
2012-04-23 |
2013-10-31 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
|
SG10201608980YA
(en)
|
2012-04-26 |
2016-12-29 |
Novartis Ag |
Antigens and antigen combinations
|
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
|
EP2852414B9
(en)
|
2012-05-22 |
2020-12-09 |
GlaxoSmithKline Biologicals SA |
Meningococcus serogroup x conjugate
|
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
|
AU2013320313B2
(en)
|
2012-09-18 |
2018-07-12 |
Glaxosmithkline Biologicals Sa |
Outer membrane vesicles
|
|
CN104582718B
(zh)
|
2012-10-03 |
2017-10-24 |
诺华股份有限公司 |
免疫原性组合物
|
|
BR122016023101B1
(pt)
|
2012-10-21 |
2022-03-22 |
Pfizer Inc |
Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
|
|
EP4272750A3
(en)
|
2013-02-07 |
2024-01-24 |
Children's Medical Center, Corp. |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
|
WO2014165271A2
(en)
|
2013-03-13 |
2014-10-09 |
Neotope Biosciences Limited |
Tau immunotherapy
|
|
CA2907915C
(en)
|
2013-04-03 |
2023-03-07 |
Allertein Therapeutics, Llc |
Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
|
|
CN112999344A
(zh)
|
2013-05-15 |
2021-06-22 |
阿尔伯达大学董事会 |
E1e2 hcv疫苗及使用方法
|
|
EP3033106A1
(en)
*
|
2013-08-14 |
2016-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunoadjuvant compositions and uses thereof
|
|
KR20200039025A
(ko)
|
2013-09-19 |
2020-04-14 |
조에티스 서비시즈 엘엘씨 |
유성 아쥬반트
|
|
EP3524262A1
(en)
|
2013-11-01 |
2019-08-14 |
Pfizer Inc |
Vectors for expression of prostate-associated antigens
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
US11191832B2
(en)
|
2013-11-19 |
2021-12-07 |
Prothena Biosciences Limited |
Monitoring immunotherapy of Lewy body disease from constipation symptoms
|
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
|
PT3116911T
(pt)
|
2014-03-12 |
2019-09-04 |
Prothena Biosciences Ltd |
Anticorpos anti-mcam e métodos de utilização associados
|
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
|
MX377794B
(es)
|
2014-03-26 |
2025-03-10 |
Glaxosmithkline Biologicals Sa |
Antigenos estafilococicos mutantes.
|
|
US20170275287A1
(en)
|
2014-08-22 |
2017-09-28 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
|
MX391930B
(es)
|
2015-01-16 |
2025-03-21 |
Zoetis Services Llc |
Vacuna contra la fiebre aftosa.
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
KR20180035807A
(ko)
|
2015-06-26 |
2018-04-06 |
세퀴러스 유케이 리미티드 |
항원적으로 매치된 인플루엔자 백신
|
|
CN107921113B
(zh)
|
2015-08-25 |
2026-08-11 |
巴比塔·阿格拉沃尔 |
免疫调节组合物及其使用方法
|
|
WO2017046776A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
|
CN117229414A
(zh)
|
2015-10-08 |
2023-12-15 |
艾伯塔大学理事会 |
丙型肝炎病毒e1/e2异二聚体及其生产方法
|
|
CA2954892A1
(en)
|
2016-01-19 |
2017-07-19 |
Pfizer Inc. |
Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
|
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
|
MX2018013384A
(es)
|
2016-05-02 |
2019-02-28 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
US10906964B2
(en)
|
2016-05-02 |
2021-02-02 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
EP3452507B1
(en)
|
2016-05-02 |
2022-10-19 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
SG11201910066QA
(en)
|
2017-05-02 |
2019-11-28 |
Prothena Biosciences Ltd |
Antibodies recognizing tau
|
|
MX2020003756A
(es)
|
2017-09-28 |
2020-07-29 |
Pfizer |
Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
|
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
|
TWI859197B
(zh)
|
2019-03-03 |
2024-10-21 |
愛爾蘭商普羅帝納生物科學公司 |
識別tau之抗體
|
|
WO2020201985A1
(en)
|
2019-04-01 |
2020-10-08 |
Pfizer Inc. |
Compositions and methods for eliciting an immune response against clostridium difficile
|
|
JP2023514825A
(ja)
|
2020-02-26 |
2023-04-11 |
ヴェルシテック リミテッド |
コロナウイルス感染症に対するpd-1ベースのワクチン
|
|
AU2021276401A1
(en)
|
2020-05-19 |
2022-12-15 |
Othair Prothena Limited |
Multi-epitope vaccine for the treatment of Alzheimer's disease
|
|
WO2021255690A2
(en)
|
2020-06-19 |
2021-12-23 |
Pfizer Inc. |
Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
|
|
AU2021297540A1
(en)
|
2020-06-24 |
2023-02-02 |
Prothena Biosciences Limited |
Antibodies recognizing sortilin
|
|
CN116472055A
(zh)
|
2020-08-07 |
2023-07-21 |
欧萨尔普罗席纳有限公司 |
治疗阿尔兹海默氏病的多表位疫苗
|
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
|
JPWO2022196701A1
(cg-RX-API-DMAC7.html)
|
2021-03-16 |
2022-09-22 |
|
|
|
EP4310095A4
(en)
|
2021-03-16 |
2025-07-23 |
Univ Osaka |
SARS-CoV-2 VIRUS-SPECIFIC FOLLICULAR HELPER T CELLS (TFH)
|
|
US20250161295A1
(en)
|
2022-04-15 |
2025-05-22 |
Yale University |
Exatecan formulation
|
|
CN116064554A
(zh)
*
|
2022-08-09 |
2023-05-05 |
常州市第三人民医院 |
一种具有免疫调节功能的核酸序列、应用及抗病毒药物
|
|
JP2024074609A
(ja)
*
|
2022-11-21 |
2024-05-31 |
ダイキン工業株式会社 |
表面処理剤
|
|
AU2023393199A1
(en)
|
2022-12-13 |
2025-05-29 |
Pfizer Inc. |
Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
|
|
AU2024341632A1
(en)
|
2023-09-15 |
2026-04-23 |
Prothena Biosciences Limited |
Compositions and methods of reducing immunogenicity and improving stability of antibodies
|
|
TW202610680A
(zh)
|
2024-05-14 |
2026-03-16 |
美商輝瑞股份有限公司 |
鋁佐劑奈米粒子、其製造方法及其用途
|
|
TW202612726A
(zh)
|
2024-06-12 |
2026-04-01 |
美商輝瑞股份有限公司 |
誘發針對困難梭狀芽孢桿菌的免疫反應之免疫原性組成物和方法
|